ATCOR Medical, Datacubed Health Partner on Patient Retention and Engagement
Collaboration to focus on digital vascular biomarker patient monitoring trial.
ATCOR Medical, a medical device developer, and Datacubed Health, an eClinical technology provider, announced a joint venture aimed to conduct trial monitoring across therapeutic programs. The teams will employ the recently FDA-approved Conneqt Pulse, a vascular biomarker device, to non-invasively provide advanced arterial health biomarkers.
ATCOR’s device tracks digital biomarkers and sends customized alerts if vascular biometrics fall within a critical range during the trial. ATCOR credits Conneqt with providing clinicians the opportunity to reduce the likelihood of adverse events. Through customized alerts programmed to alert both patients and clinicians of any potential issue, preventing an adverse event becomes more achievable.
“We are thrilled to partner with Datacubed Health and expand what is possible to elevate the patient experience and unlock the power of our digital vascular biomarkers as tools to monitor patient safety. Together we are truly personalizing decentralized trials,” stated Kimberly Tully, managing director, clinical trials partnerships, ATCOR Medical.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
